Ph 3 waveLINE-010 Trial of Zilovertamab Vedotin for the Treatment of 1L DLBCL Patients initiated February 11, 2025
First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4 February 11, 2025
Progress and Expansion of Clinical Collaboration Program for ADG126 (muzastotug) + KEYTRUDA combo in MSS CRC announced February 10, 2025
Ongoing Ph 2 trial expanded to optimize stenoparib dose and refine DRP® patient selection criteria February 10, 2025
FIRCE-1 Ph 2 Study of Firi-cel to Discontinue; Advances Remaining Programs While Evaluating Strategic Options February 4, 2025
Ph 1 SB101 Trial expanded to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas January 28, 2025
Global Ph 3 Trial of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for 1L Recurrent Head and Neck Cancer initiated January 28, 2025
Patient Enrollment milestone reached for Ph 2 Trial of Ropidoxuridine for Treatment of Patients with GBM January 28, 2025
Patients Dosed in the First Cohort of the Ph 1/2 SOLARA Trial of BH-30643 for EGFR- and HER2-Mutated NSCLC January 28, 2025
First Patient Dosed in Ph 2 Study of JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable NSCLC January 28, 2025
European Clinical Trial Sites opened and Initial Dosing of Cohort 4 completed for PAS-004 Ph 1 trial January 21, 2025
Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) announced as Lead Clinical Program January 15, 2025
Development plans of NY-500, an AI-Optimized PD-1 x VEGF Bifunctional Antibody, announced in multiple oncology indications January 15, 2025
Investigator-initiated trial (IIT) initiated in China for KJ-C2219 for the treatment of R/R B-NHL January 7, 2025
First patient enrolled in Ph 1b/2a study of BI-1607 in combination with ipilimumab and KEYTRUDA in patients with unresectable or metastatic melanoma December 26, 2024
First patient dosed in Ph 1 trial of IMC-P115C in patients with PRAME-expressing tumors December 25, 2024
